Effects of Insulin-Like Growth Factor-I and Growth Hormone in Models of Parenteral Nutrition

Journal of Parenteral and Enteral Nutrition

Volumn 23, Issue 6_suppl, 1999, Pages S184-S189

  Ney, Denise M ^a  

^a UNIVERSITY OF WISCONSIN MADISON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DEXAMETHASONE; FAT; GROWTH HORMONE; LIPID; NITROGEN; SOMATOMEDIN C;

ANIMAL EXPERIMENT; ATROPHY; BIOSYNTHESIS; CONFERENCE PAPER; CONTROLLED STUDY; GASTROINTESTINAL TRACT; HUMAN; IMMUNE SYSTEM; INSULIN SENSITIVITY; LIPID OXIDATION; MUSCLE MASS; NONHUMAN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN DEGRADATION; PROTEIN SYNTHESIS; RAT; SHORT BOWEL SYNDROME; SKELETAL MUSCLE; SMALL INTESTINE; TOTAL PARENTERAL NUTRITION; CATABOLISM; DIET SUPPLEMENTATION; MALNUTRITION; PARENTERAL NUTRITION; TREATMENT OUTCOME;

ANIMALS; ATROPHY; DRUG INTERACTIONS; GLUCOCORTICOIDS; HUMAN GROWTH HORMONE; HUMANS; INSULIN; INSULIN-LIKE GROWTH FACTOR I; INTESTINAL DISEASES; INTESTINES; NITROGEN; PARENTERAL NUTRITION, TOTAL; SHORT BOWEL SYNDROME;

EID: 0032701548     PISSN: 01486071     EISSN: 19412444     Source Type: Journal    
DOI: 10.1177/014860719902300603     Document Type: Conference Paper

References (41)

1. Buchman AL, Moukarzel AA, Bhuta S., et al. Parenteral nutrition is associated with intestinal morphologic and functional changes in humans. JPEN 19: 453-460, 1995
2. Wilmore DW: Catabolic illness: Strategies for enhancing recovery. N Engl J Med 325: 695-702, 1990
3. Clemmons DR, Underwood LE: Uses of human insulin-like growth factor-I in clinical conditions. J Clin Endocrinol Metab 79: 4-6, 1994
4. Strobl JS, Thomas MJ: Human growth hormone. Pharmacol Rev 46: 1-34, 1994
5. Mjaaland M., Unneberg K., Bjoro T., Revhang A.: Growth hormone treatment after abdominal surgery decreased carbohydrate oxidation and increased fat oxidation in patients with TPN. Metab Clin Exp 42: 185-190, 1993
6. Hintz RL, Suskind R., Amatayakul K., Thanangkul O., Olson R.: Plasma somatomedin and growth hormone values in children with protein-calorie malnutrition. J Pediatr 92: 153-156, 1978
7. Dahn MS, Lange MP, Jacobs LA: Insulin-like growth factor I production is inhibited in human sepsis. Arch Surg 123: 1409-1414, 1988
8. Clark RG, Robinson Iain CAF: Up and down the growth hormone cascade. Cytokine Growth Factor Rev 7: 65-80, 1996
9. Straus DS: Nutritional regulation of hormones and growth factors that control mammalian growth. FASEB J 8: 6-12, 1994
10. Jones JI, Clemmons DR: Insulin-like growth factors and their binding proteins: biological actions. Endocr Rev 16: 3-34, 1995
11. Thissen JP, Ketelslegers JM, Underwood LE: Nutritional regulation of the insulin-like growth factors. Endocr Rev 15: 80-101, 1994
12. Cummings JJ, D'Eugenio DB, Gross SJ: A controlled trial of dexamethasone in preterm infants at high risk for bronchopulmonary dysplasia. N Engl J Med 320: 1505-1510, 1989
13. Yang H., Grahn M., Schalch DS, et al. Anabolic effects of IGF-I coinfused with TPN in dexamethasone-Treated rats. Am J Physiol 266 (Endocrinol Metab 29): E690-698, 1994
14. Lo H-C., Hinton PS, Yang H., et al. Insulin-like growth factor-I but not growth hormone, attenuates dexamethasone-induced catabolism in parenterally fed rats. JPEN 20: 171-177, 1996
15. Leahy JL, Vandekerkhove KM: Insulin-like growth factor I at physiological concentrations is a potent inhibitor of insulin secretion. Endocrinology 126: 1593-1598, 1990
16. Mauras N., Harber FF, Haymond MW: Low dose recombinant human insulin like growth factor-I fails to affect protein metabolism but alters islet cell secretion in humans. J Clin Endocrinol Metab 75: 1192-1197, 1992
17. Lieberman SA, Butterfield GE, Harrison D., et al. Anabolic effects of recombinant insulin-like growth factor-I in cachectic patients with the acquired immunodeficiency syndrome. J Clin Endocrinol Metab 78: 404-410, 1994
18. Kudsk KA, Mowatt-Larssen C., Bukar J., et al. Effect of recombinant human insulin-like growth factor I and early TPN on immune depression following severe head injury. Arch Surg 129: 66-71. 1994
19. Kupfer SR Underwood LE, Baxter RC, et al. Enhancement of the anabolic effects of growth hormone and insulin-like growth factor-I by use of both agents simultaneously. J Clin Invest 91: 391-396, 1993
20. Zezulak KM, Green H.: The generation of insulin-like growth factor-I sensitive cells by growth hormone action. Science 233: 551-553, 1986
21. Lewitt MS, Saunders H., Phuyal JL, et al. Complex formation by human insulin-like growth factor-binding protein-3 and human acid-labile subunit in growth hormone-deficient rats. Endocrinology 134: 2404-2409, 1994
22. Lo H-C., Hinton PS, Peterson CA, et al. Simultaneous treatment with IGF-I and GH additively increases anabolism in parenterally fed rats. Am J Physiol 269 (Endocrinol Metab 32): E368-376, 1995
23. Lo H-C., Hirvonen MD, Kritsch K., et al. Growth hormone or insulin-like growth factor-I increases fat oxidation and decreases protein oxidation without altering energy expenditure in parenterally-fed rats. Am J Clin Nutr 65: 1384-1390, 1997
24. Lo H-C., Ney DM: GH and IGF-I differentially increase protein synthesis in skeletal muscle and jejunum of parenterally fed rats. Am J Physiol 271 (Endocrinol Metab 34): E872-878, 1996
25. Gore DC, Honeycott D., Jahoor F., et al. Effect of exogenous growth hormone on whole-body and isolated-limb protein kinetics in burned patients. Arch Surg 126: 38-43, 1990
26. Jacob R., Hu X., Niederstock D., et al. IGF-I stimulation of muscle protein synthesis in the awake rat: Permissive role of insulin and amino acids. Am J Physiol 270 (Endocrinol Metab 33): E60-66, 1996
27. Howarth GS, Xian CJ, Read LC: Insulin-like growth factor-I partially attenuates colonic damage in rats with experimental colitis induced by oral dextran sulphate sodium. Scand J Gastroenterol 33: 180-190, 1998
28. Peterson CA, Carey HV, Hinton PS, et al. GH elevates serum IGF-I levels but does not alter mucosal atrophy in parenterally-fed rats. Am J Physiol 272 (Gastrointest Liver Physiol 35): G1100-G1108, 1997
29. Ohneda K., Ulshen MH Fuller CR, et al. Enhanced growth of small bowel in transgenic mice expressing human insulin-like growth factor I. Gastroenterology 112: 444-454. 1997
30. Ulshen MH Dowling RH Fuller CR, et al. Enhanced growth of small bowel in transgenic mice overexpressing bovine growth hormone. Gastroenterology 104: 973-980. 1993
31. Schulman DI Hu CS, Duckett G., et al. Effects of short-Term growth hormone therapy in rats undergoing 75% small intestinal resection. J Pediatr Gastroenterol Nutr 14: 3-11, 1992
32. Park JHY. Vanderhoof JA: Growth hormone did not enhance mucosal hyperplasia after small-bowel resection. Scand J Gastroenterol 31: 349-354. 1996
33. Byrne TA, Persinger RL, Youngs LS, et al. A new treatment for patients with short-bowel syndrome: Growth hormone, glutamine. and a modified diet. Ann Surg 222: 243-255, 1995
34. Scolapio JS Camilleri M., Fleming CR, et al. Effect of growth hormone, glutamine, and diet on adaptation in short-bowel syndrome: A randomized, controlled study. Gastroenterology 113: 1074-1081, 1997
35. Klein S., Alpers DH, Grand RJ, et al. Advances in Nutrition and Gastroenterology: Summary of the 1997 ASPEN Research Workshop. JPEN 22: 3-13, 1998
36. Peterson CA, Ney DM, Hinton PS, et al. Beneficial effects of insulin-like growth factor-I on epithelial structure and function in parenterally-fed rat jejunum. Gastroenterology 111: 1501-1508, 1996
37. Taylor RG, Fuller PJ: Humoral regulation of intestinal adaptation. Clin Endo Metab 8: 165-183, 1994
38. Klein S., Kinney J., Jeejeebhoy K., et al. Nutrition support in clinical practice: review of published data and recommendations for future research directions. JPEN 21: 133-156, 1997
39. Kripke SA, DePaula JA, Berman JM, et al. Experimental short-bowel syndrome: Effect of an elemental diet supplemented with short-chain triglycerides. Am J Clin Nutr 53: 954-962, 1991
40. Gillingham M., Dahly E., Kritsch KR, et al. Effects of bowel resection and/or insulin-like growth factor-I on gut adaptation in parenterally fed rats. FASEB J 12: 2136, 1998
41. Umpleby M., Sonksen PH, Russell-Jones DL: Combined therapy with GH, IGF-I and glutamine result in net protein anabolism in the critically ill. Endocrine Society Meeting, New Orleans, LA. Abstract #OR15-4, 1998